Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis

Figure 3 Overall survival comparison between regorafenib and control treatments and sensitivity analysis of the pooled effect. A: Forest plot of overall survival (OS) comparing regorafenib vs control therapies in patients with advanced hepatocellular carcinoma. A random-effects model was used due to moderate heterogeneity (I² = 63.2%). Regorafenib was associated with a statistically significant improvement in OS (weighted mean difference = 2.54 months; 95% confidence interval: 0.26-4.81; P < 0.05); B: Sensitivity analysis of pooled OS results by sequential study exclusion. The analysis demonstrates the robustness of the OS effect estimate, showing consistent results with the omission of each individual study. CI: Confidence interval.